
Prior immune checkpoint inhibitor exposure raised mucocutaneous adverse effect risk, particularly dermatitis, with lirafugratinib in FGFR2-altered tumors.

Prior immune checkpoint inhibitor exposure raised mucocutaneous adverse effect risk, particularly dermatitis, with lirafugratinib in FGFR2-altered tumors.

In HARMONi-GI1, ivonescimab plus chemotherapy extended survival over durvalumab plus chemotherapy in untreated advanced biliary tract cancer.

Tovecimig plus paclitaxel improved objective response over paclitaxel alone in previously treated advanced biliary tract cancer in COMPANION-002.